Left ventricular assist devices (LVADs) have emerged as a beneficial therapeutic strategy
proven to improve the morbidity and mortality of patients with advanced heart failure …

Background: Heart transplantation remains the definitive therapy for patients with advanced
heart failure; however, owing to limited donor organ availability and long wait times …

Continuous-flow left ventricular assist devices (LVAD) have emerged as the standard of care
for advanced heart failure patients requiring long-term mechanical circulatory support …

Heart failure remains a significant cause of morbidity and mortality, affecting over five million
patients in the United States. Continuous-flow left ventricular assist devices (LVAD) have …

The use of long-term left ventricular assist devices (LVADs) has revolutionized the treatment
of end-stage heart failure. The most significant advance in this field has been the longer …

The utilization of left ventricular assist devices (LVADs) in end-stage heart failure has
doubled in the past ten years and is bound to continue to increase. Since the first of these …

Recent outstanding clinical advances with new mechanical circulatory systems (MCS) have
led to additional strategies in the treatment of end stage heart failure (HF). Heart …

BACKGROUND: Continuous-flow left ventricular assist devices (LVADs) such as the
HeartMate II have become the therapy of choice in patients with end-stage heart failure. The …

The field of durable left ventricular assist devices has advanced dramatically since its
introduction into the clinical realm. From the first-generation pulsatile HeartMate XVE device …

Left ventricular assist devices (LVADs) are the treatment of choice for advanced heart failure
that is refractory to medical therapy for both Bridge to Transplantation and Destination …